Preclinical efficacy studies are commonly conducted by utilizing animal models, and primary cells or immortalized cell lines. However, all these models have shortcomings, which can negatively impact the predictivity of such studies.
With the discovery of human induced pluripotent stem cell (hiPSC) technologies, we can now generate virtually any human cell type from hiPSCs. This makes the technology an ideal tool for efficacy screening studies which require human cell-based models that exhibit the disease phenotype.
At NCardia, we are specialized in the generation of hiPSC-derived cardiomyocytes. Our proprietary differentiation protocol of Pluricyte® Cardiomyocytes is serum-free and easily scalable, providing a relatively mature cardiomyocyte model without genetic modifications, with high predictivity in cardiac toxicity and efficacy assays. Based on this proprietary technology, high quality (diseased) cardiomyocytes can be generated from any individual with any genetic, ethnic or disease background. Alternatively, our healthy hiPSC-derived cardiomyocytes can be modified through addition of cytokines, hormones, chemicals or other ligands to the culture medium, or by the use of genetic technologies. In combination with specialized assay development experience, we can generate highly relevant “disease in a dish” models for efficacy studies. For more detailed and mechanistic investigations (for improved translation to in vivo, for instance), more complex in vitro techniques like 3D cultures, co-cultures with other cell types, and/or mimicking a physiologically relevant environment of the cells can be applied to create “organ-on-a-chip” models. Just let us know which features you need in the model and we can discuss the possibilities.